INO
INO
NASDAQ · Biotechnology

Inovio Pharmaceuticals Inc

$1.30
-0.06 (-4.41%)
Financial Highlights (FY 2026)
Revenue
114.7K
Net Income
-148,457,678
Gross Margin
60.1%
Profit Margin
-130,006.0%
Rev Growth
-81.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 60.1% 60.1% 61.2% 61.2%
Operating Margin -132,877.4% -119,589.8% -0.7% -0.8%
Profit Margin -130,006.0% -123,505.7% -0.8% -0.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 114.7K 619.1K 29.02M 30.84M
Gross Profit 69.0K 372.3K 17.76M 18.88M
Operating Income -152,438,316 -740,391,173 -216,172 -232,129
Net Income -148,457,678 -721,057,259 -227,719 -278,307
Gross Margin 60.1% 60.1% 61.2% 61.2%
Operating Margin -132,877.4% -119,589.8% -0.7% -0.8%
Profit Margin -130,006.0% -123,505.7% -0.8% -0.9%
Rev Growth -81.5% -81.5% +16.9% +11.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 56.78M 51.84M
Total Equity 78.40M 79.95M
D/E Ratio 0.72 0.65
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -153,882,361 -788,927,376 -290,155 -260,150
Free Cash Flow -255,634 -361,408